Cambridge, UK, 4th July, 2019: We are delighted to announce Sunil Shah, CEO, o2h Ventures, has won the prestigious UKBAA Angel Investor of the Year Award for his active participation in backing high growth potential startups and early-stage businesses in the UK. Sunil’s contribution has been instrumental in the growth of biotech in UK. He has been investing into the biotech therapeutics sector since many years – a sector from which traditionally many angel investors have stayed away.

Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.


On Thursday 4 July Dr. Fiona Marshall, Global Head of Neuroscience Discovery, MSD visited Newcastle to mark the official launch of The Biosphere.

Located at Newcastle Helix, The Biosphere is a specialist lab facility tailored to commercialisation of life sciences.  It provides biology and chemistry laboratories and high-quality office space.

Cambridge, UK, 08 July 2019: PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India.  CCBT at the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Department of Biotechnology, Government of India,.

Cambridge, UK, 8 July 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a company driving the application of gene editing and gene modulation within the global life science market, today announced that Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug (IND) application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™ shRNA technology.

Artificial Intelligence (AI) and machine learning in healthcare and life sciences holds the promise of reforming the industry. Generating and harnessing mass pools of data, the healthcare and life science industries are particularly primed to profit from the potential of AI, offering the unearthing of hidden insights in a world of unstructured data. Frost and Sullivan predicts that the health AI market, valued at US$600 million in 2014 will reach a high of US$6.2 billion by 2022.

AMSBIO reports on the pioneering research published** in a collaborative effort between researchers in the School of Engineering, University of Newcastle and Department of Pharmacology, University of Cambridge, UK that has cited Biotinylated Hyaluronan Binding Protein (biotin-HABP) supplied by the company in its investigation into the cancer resistance of the naked mole-rat (NMR).

Are you attending ON Helix 19? Do you fancy winning one of our wise owls? During the event, if you use our event hashtag (#ONHelix19) you will be automatically entered to win one of our owls!

Oxford Drug Design (ODD) wins major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures totalling over £8m to develop new antibiotics effective against drug-resistant superbugs and to expand its proprietary machine learning computational platform.

Following the recent announcement of the innovative mentoring initiative, called TechBuddy, run by Eastern AHSN and Cambridge Network to match up technology innovators in the region with people leading work in the NHS, the scheme is looking for applications from new, interested parties.

Bringing together strengths in healthcare and technology holds enormous promise for the nation’s health and wealth. There is still, however, huge scope for better understanding between technology companies and those leading work in the NHS.